CORBUS PHARMACEUTICALS HOLDINGS INC.

Company Snapshot

Founded: 2009
Entity Type: Public
Employees: 36
Region: U.S.
Headquarter: Massachusetts, U.S.
Key Geographics: U.S.
Corporate Address: 500 River Ridge Drive, Norwood, Massachusetts 02062 U.S. Tel. +1-617-963-0100 www.corbuspharma.com

Company Overview

Headquartered in Massachusetts, Corbus Pharmaceutical is a clinical-stage biopharmaceutical company focused on the provision of solutions for the treatment of fibrotic, inflammatory diseases and rare chronic disease. The company reported net sales as $4.82 million for the financial year of 2018.

Corbus’s lead product is Lenabasum, an oral, novel synthetic, particular (CB2) agonist intended to determine fibrotic and inflammation processes. Lenabasum is intended to treat cystic fibrosis disease, systemic sclerosis disease, dermatomyositis disease and systemic lupus erythematosus disease. The company’s main therapeutic areas include systemic sclerosis (SSc), dermatomyositis (DM), cystic fibrosis and systemic lupus erythematosus (SLE). Corbus has developed the CRB-4001 drug with the financial support from the National Institutes of Health (NIH). The purpose of CRB-4001 is to wipe-out blood-brain barrier penetration. In 2019, the company began the Phase I clinical investigation of CRB-4001.

Corbus is developing more than 600 novel compounds that focus on the endocannabinoid system. The company also focuses on the endocannabinoid system (ECS), which helps in the treatment of fibrosis and chronic inflammation in the body and regulates the brain activity and immune system.

CORBUS PHARMACEUTICALS HOLDINGS INC. In Reports

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

BCC Research Market Report for Chronic Disease Management. Global Chronic Disease Management market trends, with CAGRs through 2026.

OTC Drugs, Medical Devices and Diagnostics: Global Markets

Get an overview of the global markets for over-the-counter (OTC) drugs, medical devices and diagnostics. Analyses of global market trends with data from 2018 to 2019, and projections of compound annual growth rates...

Chronic Disease Management: Therapeutics, Device Technologies and Global Markets

The global market for chronic disease management therapeutics and device technologies should grow from $346 billion in 2019 to $490 billion by 2024, at a compound annual growth rate (CAGR) of 7.2% from 2019 through...

Company's Business Segments

  • Product : CRB-701, CRB-601, CRB-913, Others
  • Service : Clinical Research, Trial Management, Others

Applications/End User Industries

  • Pharmaceuticals
  • Healthcare
  • Research Organizations
  • Regulatory Bodies
  • Biotechnology
AI Sentiment